DK3222617T3 - Psma-målretningsforbindelser og anvendelser deraf - Google Patents

Psma-målretningsforbindelser og anvendelser deraf Download PDF

Info

Publication number
DK3222617T3
DK3222617T3 DK17169052.2T DK17169052T DK3222617T3 DK 3222617 T3 DK3222617 T3 DK 3222617T3 DK 17169052 T DK17169052 T DK 17169052T DK 3222617 T3 DK3222617 T3 DK 3222617T3
Authority
DK
Denmark
Prior art keywords
targeting compounds
psma targeting
psma
compounds
targeting
Prior art date
Application number
DK17169052.2T
Other languages
English (en)
Inventor
Ronnie C Mease
Sangeeta Ray
Ying Chen
Martin G Pomper
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of DK3222617T3 publication Critical patent/DK3222617T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0421—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/14—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/342—Prostate diseases, e.g. BPH, prostatitis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK17169052.2T 2009-03-19 2010-03-19 Psma-målretningsforbindelser og anvendelser deraf DK3222617T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16148409P 2009-03-19 2009-03-19
US16148509P 2009-03-19 2009-03-19
US24806709P 2009-10-02 2009-10-02
US24893409P 2009-10-06 2009-10-06
EP10754194.8A EP2408755B1 (en) 2009-03-19 2010-03-19 Urea-based peptide compounds useful for detecting inter alia prostate cancer

Publications (1)

Publication Number Publication Date
DK3222617T3 true DK3222617T3 (da) 2022-10-03

Family

ID=42740262

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17169052.2T DK3222617T3 (da) 2009-03-19 2010-03-19 Psma-målretningsforbindelser og anvendelser deraf

Country Status (11)

Country Link
US (4) US9056841B2 (da)
EP (4) EP3964498A1 (da)
CA (3) CA2755965C (da)
DK (1) DK3222617T3 (da)
ES (2) ES2636618T3 (da)
HR (1) HRP20221195T1 (da)
HU (1) HUE059796T2 (da)
LT (1) LT3222617T (da)
PL (1) PL3222617T3 (da)
PT (1) PT3222617T (da)
WO (1) WO2010108125A2 (da)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI492761B (zh) 2006-11-08 2015-07-21 Molecular Insight Pharm Inc 麩胺酸之異二聚物
CN104873982A (zh) 2007-08-17 2015-09-02 普渡研究基金会 Psma结合配体-接头缀合物及其使用方法
US9422234B2 (en) * 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
DK3222617T3 (da) 2009-03-19 2022-10-03 Univ Johns Hopkins Psma-målretningsforbindelser og anvendelser deraf
US20180009767A9 (en) 2009-03-19 2018-01-11 The Johns Hopkins University Psma targeted fluorescent agents for image guided surgery
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2012135592A2 (en) 2011-03-31 2012-10-04 The Johns Hopkins University Theranostic imaging agents and methods of use
EP2739316B1 (en) * 2011-08-05 2019-04-10 Molecular Insight Pharmaceuticals, Inc. Radiolabeled prostate specific membrane antigen inhibitors
CA2846629C (en) 2011-08-25 2023-08-01 University Of Central Florida Research Foundation, Inc. Methods and compositions comprising a c-terminal bax peptide
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
EP2785712B1 (en) * 2011-11-30 2019-05-01 The Johns Hopkins University Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (pmsa) and uses thereof
WO2013130177A1 (en) * 2012-02-28 2013-09-06 Cornell University Psma as a biomarker for androgen activity in prostate cancer
EP3858341A1 (en) 2012-11-15 2021-08-04 Endocyte, Inc. Psma ligand-containing conjugates for the treatment of prostate cancer
FR2998298B1 (fr) 2012-11-21 2020-11-20 Univ Bourgogne Synthese de sels d’imidazo[1,2-a]pyrazin-4-ium pour la synthese du 1,4,7-triazacyclononane (tacn) et de ses derives n- et/ou c-fonctionnalises
US9447121B2 (en) * 2013-01-14 2016-09-20 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
CN105407920B (zh) * 2013-05-03 2019-12-13 耶鲁大学 靶向癌症、尤其是***癌的合成性抗体模拟化合物(SyAMs)
WO2015057692A1 (en) * 2013-10-14 2015-04-23 The Johns Hopkins University Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy
US10406246B2 (en) 2013-10-17 2019-09-10 Deutsches Kresbsforschungszentrum Double-labeled probe for molecular imaging and use thereof
KR101947053B1 (ko) 2013-10-18 2019-02-12 도이체스 크렙스포르슝스첸트룸 전립선 특이적 막 항원（ｐｓｍａ）의 표지된 억제제, 조영제로서의 이의 용도 및 전립선암 치료용 약제
EP3777898A3 (en) * 2013-11-14 2021-04-21 Endocyte, Inc. Compounds for positron emission tomography
WO2015142860A1 (en) * 2014-03-18 2015-09-24 The Methodist Hospital System Ph sensitive fluorescent compounds and methods for tumor detection
EP3140282B1 (en) * 2014-05-06 2019-07-10 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
CA2949365A1 (en) * 2014-05-16 2015-11-19 Memorial Sloan Kettering Cancer Center One-step labeling of antibodies to high specific activity with actinium-225
US10588972B2 (en) 2014-06-02 2020-03-17 Li-Cor, Inc. Phthalocyanine probes and uses thereof
EP3170003A4 (en) 2014-07-18 2018-03-28 University of Central Florida Research Foundation, Inc. Methods and compositions comprising a ct20 peptide
WO2016030329A1 (en) * 2014-08-24 2016-03-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
US10736974B2 (en) * 2014-10-22 2020-08-11 The Johns Hopkins University Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy
US9886665B2 (en) * 2014-12-08 2018-02-06 International Business Machines Corporation Event detection using roles and relationships of entities
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2016176462A1 (en) * 2015-04-28 2016-11-03 University Of Central Florida Foundation, Inc. Methods and compositions for theranostic nanoparticles
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US20180158559A1 (en) * 2015-06-05 2018-06-07 Ncm Usa Bronx Llc Method and system for producing gallium-68 radioisotope by solid targeting in a cyclotron
WO2017021385A1 (en) * 2015-08-06 2017-02-09 F. Hoffmann-La Roche Ag Processes for the preparation of galnac acid derivatives
US20180236109A1 (en) * 2015-08-20 2018-08-23 Universitat Zu Koln Pain Tracking by PET-imaging (Pain-TraP)
US10842887B2 (en) * 2015-09-09 2020-11-24 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
US9808538B2 (en) 2015-09-09 2017-11-07 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
PL3356385T3 (pl) 2015-09-30 2021-06-28 Deutsches Krebsforschungszentrum Tagowane 18F inhibitory antygenu błonowego specyficznego dla gruczołu krokowego (PSMA) i ich zastosowanie jako środków do obrazowania w nowotworze gruczołu krokowego
US10898594B2 (en) 2015-10-27 2021-01-26 The Johns Hopkins University PAMAM dendrimer based CEST imaging agents and uses thereof
US10405753B2 (en) * 2015-11-10 2019-09-10 Intuitive Surgical Operations, Inc. Pharmaceutical compositions of near IR closed chain, sulfo-cyanine dyes
WO2017084987A1 (en) 2015-11-16 2017-05-26 F. Hoffmann-La Roche Ag GalNAc CLUSTER PHOSPHORAMIDITE
SI3925952T1 (sl) 2016-03-22 2024-03-29 The Johns Hopkins University Za prostato specifična, na membranski antigen usmerjena visoko afinitetna sredstva za endoradioterapijo raka prostate
US20170296679A1 (en) * 2016-04-18 2017-10-19 Intuitive Surgical Operations, Inc. Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands
US10980902B2 (en) 2016-07-14 2021-04-20 University Of Central Florida Research Foundation, Inc. Bi-DOTA complex-loaded dendritic polymer nanoparticles
MX2019005742A (es) * 2016-11-23 2019-09-13 Cancer Targeted Tech Llc Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.
US10975060B2 (en) 2016-11-28 2021-04-13 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
WO2018136681A1 (en) 2017-01-20 2018-07-26 Regeneron Pharmaceuticals, Inc. Rotatable surgical table
JP7373998B2 (ja) 2017-05-02 2023-11-06 コーネル・ユニバーシティー 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬
WO2018215049A1 (en) 2017-05-23 2018-11-29 F. Hoffmann-La Roche Ag Process for galnac oligonucleotide conjugates
US11478558B2 (en) 2017-05-30 2022-10-25 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
EP3634474A1 (en) 2017-06-09 2020-04-15 GEMoaB Monoclonals GmbH Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders
WO2018232280A1 (en) * 2017-06-15 2018-12-20 The Johns Hopkins University Psma targeted fluorescent agents for image guided surgery
EP3668518A1 (en) 2017-08-18 2020-06-24 Li-Cor, Inc. Sonodynamic therapy
JP2021500373A (ja) 2017-10-23 2021-01-07 ザ・ジョンズ・ホプキンス・ユニバーシティ 線維芽細胞活性化タンパク質α（ＦＡＰ−α）を標的とする撮像剤および放射線療法用薬剤
JP2021502399A (ja) 2017-11-13 2021-01-28 ドイチェス クレブスフォルシュンクスツェントルム 分子イメージングのための二重標識プローブ及びその使用
CN111356482A (zh) * 2017-11-21 2020-06-30 德国癌症研究中心 用于分子成像的双标记的探针及其用途
JP2021513542A (ja) 2018-02-06 2021-05-27 ザ・ジョンズ・ホプキンス・ユニバーシティ がん放射線治療法のための、ｐｓｍａをターゲットとした放射性ハロゲン化した尿素‐ポリアミノカルボン酸塩
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
EP3781019A4 (en) * 2018-04-17 2022-04-13 Cornell University FLUORINE-18 LABELED COMPOSITIONS AND THEIR USE IN BIOLOGICAL TISSUE IMAGING
WO2020028323A1 (en) * 2018-07-30 2020-02-06 The Johns Hopkins Universtiy Competitive prostate-specific membrane antigen (psma) binding agents for the reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy
EP3636635A1 (en) 2018-10-11 2020-04-15 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Imaging agents
PE20211471A1 (es) 2018-11-23 2021-08-05 Bayer Ag Formulacion de medios de contraste y proceso para prepararlos
BR112021015109A2 (pt) 2019-01-30 2022-01-11 Coherent Biopharma Suzhou Ltd Conjugado de fármaco-ligante duplo e uso do mesmo
CN113117100B (zh) * 2019-12-31 2024-03-01 广东精观生物医药科技有限公司 一种靶向psma的荧光分子探针及其制备方法和应用
EP4185336A1 (en) * 2020-07-23 2023-05-31 Technische Universität München Silicon-containing ligand compounds
EP4244216A1 (en) 2020-11-12 2023-09-20 ABX Advanced Biochemical Compounds GmbH Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks
JP2024513906A (ja) 2021-04-07 2024-03-27 センチュリー セラピューティクス，インコーポレイテッド 人工多能性幹細胞からアルファ－ベータｔ細胞を生成するための組成物および方法
WO2022216514A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
CA3214661A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
WO2023240147A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof
WO2024064969A2 (en) 2022-09-23 2024-03-28 Nuclidium Ag High-purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6159657A (en) 1999-08-31 2000-12-12 Eastman Kodak Company Thermal imaging composition and member containing sulfonated ir dye and methods of imaging and printing
JP2004509152A (ja) 2000-05-12 2004-03-25 ユニバーシティ　ホスピタル 放射性金属標識分子のプロキレート剤
US6663847B1 (en) 2000-10-13 2003-12-16 Mallinckrodt Inc. Dynamic organ function monitoring agents
BR0115584A (pt) 2000-11-24 2003-09-23 Breath Ltd Esterilização de produtos farmacêuticos
CA2473289C (en) 2002-01-10 2014-07-29 The Johns Hopkins University Asymmetric urea compounds useful as naaladase and psma imaging agents
FR2903952B1 (fr) 2006-07-21 2009-06-12 Renault Sas Dispositif et procede de surveillance de la commande du braquage de roue arriere directrice.
WO2008109832A2 (en) 2007-03-08 2008-09-12 Visen Medical, Inc. Viable near-infrared fluorochrome labeled cells and methods of making and using same
WO2009002529A2 (en) * 2007-06-26 2008-12-31 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
CN104873982A (zh) 2007-08-17 2015-09-02 普渡研究基金会 Psma结合配体-接头缀合物及其使用方法
US9422234B2 (en) * 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
JP2009169768A (ja) 2008-01-17 2009-07-30 Fuji Xerox Co Ltd 情報処理装置及びプログラム
WO2010065899A2 (en) * 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
US20180009767A9 (en) 2009-03-19 2018-01-11 The Johns Hopkins University Psma targeted fluorescent agents for image guided surgery
DK3222617T3 (da) 2009-03-19 2022-10-03 Univ Johns Hopkins Psma-målretningsforbindelser og anvendelser deraf
EP2785712B1 (en) * 2011-11-30 2019-05-01 The Johns Hopkins University Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (pmsa) and uses thereof
EP3601724A4 (en) 2017-03-28 2020-12-23 Baker Hughes, a GE company, LLC WIRE ROPE, IN PARTICULAR WITH SELF-SUPPORTING ROPE

Also Published As

Publication number Publication date
US20230348405A1 (en) 2023-11-02
PT3222617T (pt) 2022-09-30
US20220259161A1 (en) 2022-08-18
CA2755965C (en) 2019-04-16
EP3964502A1 (en) 2022-03-09
EP3222617B1 (en) 2022-07-06
LT3222617T (lt) 2022-10-25
WO2010108125A3 (en) 2011-03-24
CA3035532C (en) 2021-10-26
US9056841B2 (en) 2015-06-16
EP2408755A2 (en) 2012-01-25
WO2010108125A2 (en) 2010-09-23
EP2408755B1 (en) 2017-05-03
EP2408755A4 (en) 2012-09-12
US11661402B2 (en) 2023-05-30
CA3131469A1 (en) 2010-09-23
PL3222617T3 (pl) 2023-01-02
EP3222617A1 (en) 2017-09-27
HUE059796T2 (hu) 2022-12-28
US20120009121A1 (en) 2012-01-12
US9776977B2 (en) 2017-10-03
US20150104387A1 (en) 2015-04-16
HRP20221195T1 (hr) 2022-12-09
CA2755965A1 (en) 2010-09-23
ES2928480T3 (es) 2022-11-18
ES2636618T3 (es) 2017-10-06
EP3964498A1 (en) 2022-03-09
CA3035532A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
DK3222617T3 (da) Psma-målretningsforbindelser og anvendelser deraf
DK2437790T3 (da) Konjugeringsfremgangsmåder
DK2462134T3 (da) N1-sulfonyl-5-fluorpyrimidinonderivater
DK2414015T3 (da) Laryngoskopsystem
DE112010004215A5 (de) Hydrostataktor
DE112010002949A5 (de) Kupplungstastpunkte
DK2411442T4 (da) Umættet polyesterresin
BRPI1008827A2 (pt) deisobutenizador
DK2430035T3 (da) Uracylspipooxetannukleosider
BRPI1014968A2 (pt) subalargador
DE112010002728A5 (de) Turboinhalator
DE112009005323A5 (de) Hebelarmprüfmaschine
DE112010004249A5 (de) Spindelaktor
DE112009005462T8 (de) Lenkungsssteuervorrichtung
BR112012004964A2 (pt) girocóptero
BRPI1008070A2 (pt) tricianoboratos
DK2483126T3 (da) Skinnekøretøj
DE112010004865T8 (de) Lamellennassreibkupplung
DK2506968T3 (da) Faujasit-zeolit
DE112010003255A5 (de) Fördergutverteiler
BRPI1010159A2 (pt) bistuti
DE602010000025D1 (de) Fahrzeugsitzgurtvorrichtung
BRPI0924738A2 (pt) Herbicidas
ES1070429Y (es) Traspaleta mejorada
BR112012003616A2 (pt) metilpirroloprimidinacarboxamidas